(NASDAQ: OKYO) Okyo Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.77%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.33%.
Okyo Pharma's earnings in 2026 is -$8,949,657.On average, 4 Wall Street analysts forecast OKYO's earnings for 2027 to be -$12,044,051, with the lowest OKYO earnings forecast at -$15,428,981, and the highest OKYO earnings forecast at -$8,265,526. On average, 3 Wall Street analysts forecast OKYO's earnings for 2028 to be -$47,640,915, with the lowest OKYO earnings forecast at -$45,772,643, and the highest OKYO earnings forecast at -$49,042,118.
In 2029, OKYO is forecast to generate -$45,499,750 in earnings, with the lowest earnings forecast at -$43,715,446 and the highest earnings forecast at -$46,837,978.